Assuming conservative lecanemab uptake rates of 1.1–2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...

Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted ...